Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Acute Promyelocytic Leukemia: Remission Induction With ATRA + Idarubicin (AIDA) Risk Adapted Intensity of Consolidation and Addition of ATRA Maintenance With ATRA + Methotrexate + Mercaptopurine Salvage Therapy for Molecular and Haematological Relapses

NCT00465933 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00465933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00465933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Acute Promyelocytic Leukemia: Remission Induction With ATRA + Idarubicin (AIDA) Risk Adapted Intensity of Consolidation and Addition of ATRA Maintenance With ATRA + Methotrexate + Mercaptopurine Salvage Therapy for Molecular and Haematological Relapses
Lead sponsor
PETHEMA Foundation
Phase
Phase 4
Overall status
Completed
Start date
March 31, 1999
Completion date
November 30, 2007
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukemia